Document is current
Any future updates will be listed below
-
Authors
Ramgopal, Moti
Mezzio, Dylan J.
Dunn, Keith
Liu, Shan-Yu
Paul, Damemarie
Rhee, Martin S.
Castagna, Antonella
-
Funding
Funding for this research was provided by:
Gilead Sciences (NCT04150068)
- License Information
-
More Information
Article History
Accepted: 9 January 2025
First Online: 10 March 2025
Declarations
:
: Moti Ramgopal has served as a consultant for Merck; ViiV Healthcare; and Gilead Sciences, Inc.; and has been a member of the speakers bureau for AbbVie; Gilead Sciences, Inc.; ViiV Healthcare; and Janssen.Dylan J. Mezzio, Keith Dunn, Shan-Yu Liu, and Martin S. Rhee are employees of Gilead Sciences, Inc., and may hold stock options.Damemarie Paul was an employee of Gilead Sciences, Inc., at the time this work was done and may hold Gilead stock.Antonella Castagna reports funding, participation in advisory boards and speaker panels, and preparation of educational materials from ViiV Healthcare; Gilead Sciences, Inc.; Merck Sharp and Dohme; Janssen; and Cilag.
